钠-葡萄糖共转运蛋白2抑制剂在老年2型糖尿病合并常见心血管疾病中的应用进展
CSTR:
作者:
作者单位:

(1. 中国人民解放军总医院京西医疗区,北京 100144;2. 中国人民解放军总医院第六医学中心心血管病学部,北京 100048)

作者简介:

通讯作者:

中图分类号:

基金项目:

国家自然科学基金(82200366,82370327)


Advances in application of sodium-glucose co-transporter 2 inhibitor in elderly type 2 diabetes mellitus patients with concomitant common cardiovascular diseases
Author:
Affiliation:

(1. Western Medical Branch, Chinese PLA General Hospital, Beijing 100144, China;2. Senior Department of Cardiology, Sixth Medical Centre, Chinese PLA General Hospital, Beijing 100048, China)

Fund Project:

This work was supported by the National Natural Science Foundation of China (82200366, 82370327).

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    老年2型糖尿病(T2DM)患者常有多病共存现象,而合并心血管疾病(CVD)最为常见,是其致残、致死的首要原因。钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)是一种新型降糖药物,其心血管保护作用受到广泛关注,在老年T2DM与CVD共病的治疗上展现出良好的前景。本文就SGLT2i在T2DM合并心力衰竭、高血压、动脉粥样硬化、心肌梗死等常见CVD中的应用研究进展作一综述。

    Abstract:

    Elderly patients with type 2 diabetes mellitus (T2DM) often have multiple coexisting diseases, and the complication of cardiovascular diseases (CVD) is the most common, which is the primary cause of disability and death. Sodium-glucose co-transporter protein 2 inhibitor (SGLT2i) is a novel hypoglycemic agent, which has received widespread attention for its cardio-protective effects, and shows good prospects for the treatment of co-morbidities of T2DM and CVD in the elderly. In this article, we reviewed the progress of SGLT2i in T2DM combined with heart failure, hypertension, atherosclerosis, myocardial infarction and other common CVD.

    参考文献
    相似文献
    引证文献
引用本文

张辉,李泱,刘传斌.钠-葡萄糖共转运蛋白2抑制剂在老年2型糖尿病合并常见心血管疾病中的应用进展[J].中华老年多器官疾病杂志,2024,23(8):624-627
DOI:10.11915/j. issn.1671-5403.2024.08.138

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2023-11-07
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-08-23
  • 出版日期:
文章二维码